Biopharmaceutical company DiscGenics has named Jeff Poole as its first CFO, according to a Sept. 9 news release.
Four things to know:
1. Mr. Poole has held several executive roles at Medtronic over a 13-year period.
2. Most recently, he served as vice president of finance for Medtronic Spine and Biologics, a global business unit with more than $2.5 billion in annual revenue.
3. Mr. Poole speaks fluent Japanese and has lived and worked in Japan, where DiscGenics has a significant commercial interest.
4. DiscGenics has secured more than $71 million in funding to date and is focusing on clinical trials of its allogeneic, injectable disc cell therapy for lumbar degenerative disc disease.